[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].

Antoni Benabarre; P Castro; José Sánchez‐Moreno; Anabel Martínez‐Arán; Manel Salamero; Andréa Murru; Carolina Franco; Eduard Vieta

[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder].

Article 2010 en

Abstract

1 min read

LAIR could be an effective maintenance therapy for bipolar and schizoaffective patients with poor compliance to oral treatment.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2001

Efficacy and Safety of Risperidone in the Treatment of Schizoaffective Disorder

Eduard Vieta, Marisa Herraiz, Antonio García Fernández, Cristòbal Gastó, Antonio Benabarre, Francesc Colom, Anabel Martínez‐Arán

Article2001

Risperidone Safety and Efficacy in the Treatment of Bipolar and Schizoaffective Disorders

Eduard Vieta, José Manuel Goikolea, Bàrbara Corbella, Antonio Benabarre, María Reinares, G. Martínez, Antonio García Fernández, Francesc Colom, Anabel Martínez‐Arán

Article2010

Developing an Individualized Treatment Plan for Patients With Schizoaffective Disorder

Eduard Vieta

Article2008

A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

Eduard Vieta, E. Nieto, Aurea Autet, Adriane Ribeiro Rosa, José Manuel Goikolea, Núria Cruz, Pere Bonet

Article2001

Bipolar disorder, schizoaffective disorder and schizophrenia: epidemiologic, clinical and prognostic differences

Antonio Benabarre, Eduard Vieta, Francesc Colom, Anabel Martínez‐Arán, María Reinares, Cristòbal Gastó